Results 31 to 40 of about 4,485 (189)

The Current Status of Latency Reversing Agents for HIV-1 Remission [PDF]

Annual Review of Virology, 2021
Combinatory antiretroviral therapy (cART) reduces human immunodeficiency virus type 1 (HIV-1) replication but is not curative because cART interruption almost invariably leads to a rapid rebound of viremia due to the persistence of stable HIV-1-infected cellular reservoirs.
Rodari, Anthony, Darcis, Gilles, Van Lint, Carine   +2 more
openaire   +3 more sources

Croton oligandrus Pierre & Hutch (Euphorbiaceae) Extracts and Isolated Compounds Reverse HIV-1 Latency [PDF]

Journal of Experimental Pharmacology
Chantal Emade Nkwelle,1,2 Smith B Babiaka,3,4 Clovis S Metuge,2,3 Kimberly Liang,5 Unique Stephens,5 Seraphine Nkie Esemu,1 David S Zuzga,5 Kristy Shuda McGuire,5 Luis J Montaner,5 Roland N Ndip,1 Ian Tietjen,5 Fidele Ntie-Kang2,3,6 1Department of ...
Emade Nkwelle C, Babiaka SB, Metuge CS, Liang K, Stephens U, Esemu SN, Zuzga DS, Shuda McGuire K, Montaner LJ, Ndip RN, Tietjen I, Ntie-Kang F   +11 more
doaj   +2 more sources

Cleavage and Polyadenylation Specificity Factor 6 Is Required for Efficient HIV-1 Latency Reversal. [PDF]

mBio, 2021
CPSF6 is a cellular factor that regulates cleavage and polyadenylation of mRNAs and participates in HIV-1 infection by facilitating targeting of preintegration complexes to the chromatin. Our observations reveal a second role of CPSF6 in the HIV-1 life cycle that involves regulation of viral transcription through controlling the stability of protein ...
Zheng Y, Schubert HL, Singh PK, Martins LJ, Engelman AN, D'Orso I, Hill CP, Planelles V.   +7 more
europepmc   +4 more sources

The BAF complex inhibitor pyrimethamine reverses HIV-1 latency in people with HIV-1 on antiretroviral therapy [PDF]

Science Advances, 2023
Reactivation of the latent HIV-1 reservoir is a first step toward triggering reservoir decay. Here, we investigated the impact of the BAF complex inhibitor pyrimethamine on the reservoir of people living with HIV-1 (PLWH). Twenty-eight PLWH on suppressive antiretroviral therapy were randomized (1:1:1:1 ratio) to receive pyrimethamine, valproic acid ...
Prins, Henrieke A. B., Crespo, Raquel, Lungu, Cynthia, Rao, Shringar, Li, Letao, Overmars, Ronald J., Papageorgiou, Grigorius, Mueller, Yvonne M., Stoszko, Mateusz, Hossain, Tanvir, Kan, Tsung Wai, Rijnders, Bart J. A., Bax, Hannelore I., van Gorp, Eric C. M., Nouwen, Jan L., de Vries-Sluijs, Theodora E. M. S., Schurink, Carolina A. M., de Mendonça Melo, Mariana, van Nood, Els, Colbers, Angela, Burger, David, Palstra, Robert-Jan, van Kampen, Jeroen J. A., van de Vijver, David A. M. C., Mesplède, Thibault, Katsikis, Peter D., Gruters, Rob A., Koch, Birgit C. P., Verbon, Annelies, Mahmoudi, Tokameh, Rokx, Casper   +30 more
openaire   +6 more sources

NSC95397 Is a Novel HIV-1 Latency-Reversing Agent

Viruses, 2023
The latent viral reservoir represents one of the major barriers to curing HIV-1. Focus on the “kick and kill” (also called “shock and kill”) approach, in which virus expression is reactivated, and then cells producing virus are selectively depleted, has led to the discovery of many latency-reversing agents (LRAs) that have furthered our understanding ...
Randilea Nichols Doyle, Vivian Yang, Yetunde I. Kayode, Robert Damoiseaux, Harry E. Taylor, Oliver I. Fregoso   +5 more
openaire   +6 more sources

DataSheet_1_Natural killer cells induce HIV-1 latency reversal after treatment with pan-caspase inhibitors.pdf [PDF]

, 2022
The establishment of a latency reservoir is the major obstacle for a cure of HIV-1. The shock-and-kill strategy aims to reactivate HIV-1 replication in HIV -1 latently infected cells, exposing the HIV-1-infected cells to cytotoxic lymphocytes.
Robert van Domselaar (9436448), George Gourgi (14222852), Luca Love (12800641), Joana Furtado Milão (14222849), Lukas Derhaschnig (14222855), J. Peter Svensson (8378355), Anders Sönnerborg (153581)   +6 more
core   +1 more source

Human Immunodeficiency Virus-1 Latency Reversal via the Induction of Early Growth Response Protein 1 to Bypass Protein Kinase C Agonist-Associated Immune Activation

Frontiers in Microbiology, 2022
Human Immunodeficiency Virus-1 (HIV) remains a global health challenge due to the latent HIV reservoirs in people living with HIV (PLWH). Dormant yet replication competent HIV harbored in the resting CD4+ T cells cannot be purged by antiretroviral ...
Lilly M. Wong, Dajiang Li, Yuyang Tang, Gema Méndez-Lagares, George R. Thompson, Dennis J. Hartigan-O’Connor, Satya Dandekar, Guochun Jiang, Guochun Jiang   +8 more
doaj   +1 more source

Inhibitors of Signaling Pathways That Block Reversal of HIV-1 Latency [PDF]

Antimicrobial Agents and Chemotherapy, 2019
Signaling pathways play a key role in HIV-1 latency. In this study, we used the 24ST1NLESG cell line of HIV-1 latency to screen a library of structurally diverse, medicinally active, cell permeable kinase inhibitors, which target a wide range of signaling pathways, to identify inhibitors of HIV-1 latency reversal.
Benni, Vargas, Nicholas S, Giacobbi, Anwesha, Sanyal, Narasimhan J, Venkatachari, Feng, Han, Phalguni, Gupta, Nicolas, Sluis-Cremer   +6 more
openaire   +2 more sources

Secreted factors induced by PKC modulators do not indirectly cause HIV latency reversal [PDF]

, 2023
HIV can establish a long-lived latent infection in cells harboring integrated non-expressing proviruses. Latency reversing agents (LRAs), including protein kinase C (PKC) modulators, can induce expression of latent HIV, thereby reducing the latent ...
Hourani, Rami, Marsden, Matthew D, Kim, Jocelyn T, Wender, Paul A, Ranjan, Alok, Zack, Jerome A, Moran, Jose A   +6 more
core   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source